Authors
Latest:
Dr. Maziéres on the Evaluation of Tepotinib Plus Osimertinib in EGFR-mutated NSCLCJulien Maziéres, MD, PhD, discusses the evaluation of tepotinib plus osimertinib in EGFR-mutated non–small cell lung cancer.
Latest:
Dr Mohan on CAR T-cell Therapies and Bispecific Antibodies in R/R Multiple MyelomaMeera Mohan, MD, MS, FACP, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma.
Latest:
Dr Chambers on the Importance of Patient Counseling in Ovarian CancerLaura J. Chambers, DO, discusses the importance of treatment counseling for patients with ovarian cancer considering PARP inhibitor therapy.
Latest:
Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALLSujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.
Latest:
Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in MelanomaMattia Garutti, MD, discusses the potential shift to neoadjuvant therapy in melanoma.
Latest:
Review of the SELECT-AML-1 Trial and the Future of Newly Diagnosed AMLDaniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.
Latest:
Dr. Azad on the Significance of the PROfound Trial in mCRPCArun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.
Latest:
Dr. Farrington on the Importance of Genetic Testing in CRCCaroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.
Latest:
Basal Cell Carcinoma Clinical PearlsDrs Babakoohi and Atlas share clinical pearls for community oncologists on treating basal cell carcinoma.
Latest:
Dr Nagpal on the FDA Approval of Vorasidenib for Grade 2 Astrocytoma or OligodendrogliomaSeema Nagpal, MD, discusses the FDA approval of vorasidenib for patients with astrocytoma or oligodendroglioma harboring IDH1 or IDH2 mutations.
Latest:
Dr Gruenwald on Tumor Responses With Lenvatinib Plus Pembrolizumab in Advanced RCCViktor Gruenwald, MD, PhD, discusses key results from a post-hoc analysis of the phase 3 CLEAR trial in advanced renal cell carcinoma.
Latest:
Dr Lin on the Effect of Perioperative Treatment on Surgical Approaches in NSCLCJules Lin, MD, discusses how approaches to surgical intervention in non–small cell lung cancer may have shifted with the increasing use of targeted therapy and immunotherapies in the adjuvant and neoadjuvant setting.
Latest:
Dr. Wang on the Rationale for Viral Hepatitis Screening to Prevent HCCSu H. Wang, MD, MPH, discusses the rationale for the integration of viral hepatitis screening and care in a hospital system as the first steps for preventing liver cancers like hepatocellular carcinoma.
Latest:
Dr Jones on the Application of ctDNA Testing in CRCJeremy C. Jones, MD, discusses the applications of circulating tumor DNA testing in colorectal cancer.
Latest:
BASECAMP-1 Trial Aims to Identify Patients With Solid Tumors Who Are Eligible for A2B530The observational BASECAMP-1 screening study has started to identify patients with advanced solid tumors harboring somatic human leukocyte antigen-A*02 loss of heterozygosity who would be eligible to receive the novel Tmod CAR T-cell therapy, A2B530, if their cancer relapses after standard of care treatment.
Latest:
Dr. Lister on Selecting Patients With Lymphoma for CAR T-Cell TherapyJohn Lister, MD, discusses selecting patients with lymphoma for CAR T-cell therapy.
Latest:
Dr Frank on the Background of Investigating CAR22 Therapy in Relapsed/Refractory LBCLMatthew Frank, MD, PhD, discusses findings from prior research investigating a CD22-directed CAR T-cell therapy that informed the rationale for launching a phase 1 trial with this agent in patients with relapsed/refractory large B-cell lymphoma.
Latest:
Dr Jeselsohn on Enrollment Criteria For the VERITAC-2 Trial in ER+ Breast CancerRinath M. Jeselsohn, MD, discusses enrollment criteria for the phase 3 VERITAC-2 trial, as well as the potential clinical implications of this research for patients with advanced estrogen receptor–positive/HER2-negative metastatic breast cancer.
Latest:
Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MDDrs Camidge and Ney discuss Dr Ney’s journey to becoming a neurologic oncologist and his experience as a physician with Tourette syndrome.
Latest:
Dr. Nguyen on Primary Analysis of the FORMULA-509 Trial in Prostate CancerPaul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.
Latest:
Dr. Fleury on the Advancement of Decentralized Clinical Trials During COVID-19Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.
Latest:
Metastatic CRPC: Novel Treatment Strategies With Radioligand TherapyKey opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.
Latest:
Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid TumorsSachdev P. Thomas, MD, discusses the utility of the immunotherapy response score when predicting clinical benefit with pembrolizumab in advanced solid tumors.
Latest:
Dr Modi on Updated OS Data From the DESTINY-Breast04 Trial of T-DXd in HER2-Low Breast CancerShanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.
Latest:
Student Loan Debt, Immigration Status Often Drive Career Decisions for FellowsInvestigators from Indiana University decided to study some of the factors influencing career plans for physicians, focusing on current fellows and recent graduates of the hematology and medical oncology specialty in the United States.
Latest:
CAR T-Cell Therapy in Metastatic CRPC and Future Directions in CareClosing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
Latest:
Dr Hwang on the Potential Use of Multicancer Early Detection Tests in Breast Cancer ScreeningShelley Hwang, MD, MPH, discusses the potential use of multicancer early detection tests in breast cancer screening.
.jpg?fit=crop&auto=format)
